UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk

The journals of gerontology. Series A, Biological sciences and medical sciences, 2023-12, Vol.78 (12), p.2426-2434

2023

Volltextzugriff (PDF)

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure

Journal of the American Heart Association, 2022-02, Vol.11 (4), p.e022376

2022

Volltextzugriff (PDF)

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Cardiovascular diabetology, 2024-02, Vol.23 (1), p.57-12, Article 57

2024

Volltextzugriff (PDF)

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Cardiovascular diabetology, 2024-03, Vol.23 (1), p.103-103, Article 103

2024

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Annals of internal medicine, 2021-11, Vol.174 (11), p.1528-1541

2021

Volltextzugriff (PDF)

Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-Time

American journal of epidemiology, 2019-06, Vol.188 (6), p.1016-1022

2019

Volltextzugriff (PDF)

870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

270-OR: Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes—Results from the EMPRISE study

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Effectiveness and safety of empagliflozin: final results from the EMPRISE study

Diabetologia, 2024-07, Vol.67 (7), p.1328-1342

2024

Volltextzugriff (PDF)

Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data

American journal of epidemiology, 2022-03, Vol.191 (5), p.908-920

2022

Volltextzugriff (PDF)

179-OR: Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

1079-P: Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Stratified analysis in comparative effectiveness studies that emulate randomized trials

Pharmacoepidemiology and drug safety, 2024-01, Vol.33 (1), p.e5716-n/a

2024

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Annals of internal medicine, 2022-01, Vol.175 (1), p.W4

2022

Volltextzugriff (PDF)

Renin–Angiotensin–Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries

Epidemiology (Cambridge, Mass.), 2019-11, Vol.30 (6), p.867-875

2019

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Annals of internal medicine, 2022-01, Vol.175 (1), p.W4-W5

2022

Volltextzugriff (PDF)

Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors

European journal of clinical pharmacology, 2016-08, Vol.72 (8), p.1013-1023

2016

Volltextzugriff (PDF)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

JAMA network open, 2022-10, Vol.5 (10), p.e2237606-e2237606

2022

Volltextzugriff (PDF)

A Systematic Approach to Evaluating Instrumental Variable Assumptions: Applied Example of Glucose-lowering Medications and Risk for Hospitalized Heart Failure in Older Adults

American journal of epidemiology, 2024-09

2024

Volltextzugriff (PDF)

Estimating Treatment Effects in the Presence of Calendar Time Trends in Prescribing: Instrumental Variables and Trend-In-Trend Design

Htoo, Phyo T

2020

Volltextzugriff (PDF)

Unmeasured confounding with and without randomization

Pragmatic Randomized Clinical Trials, 2021

2021

Volltextzugriff (PDF)

Chapter 14 - Unmeasured confounding with and without randomization

Pragmatic Randomized Clinical Trials, 2021, p.185-205

2021

Volltextzugriff (PDF)

Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme

The Lancet (British edition), 2018-05, Vol.391 (10133), p.1916-1926

2018

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Humans
(18)
Diabetes Mellitus
(10)
Aged
(9)
Diabetes
(9)
Female
(9)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Medicare
(8)
Cardiovascular Diseases
(7)
Glucagon
(7)
Male
(7)
Myocardial Infarction
(7)
Cardiovascular Diseases - Epidemiology
(6)
Cerebral Infarction
(6)
Cohort Studies
(6)
Congestive Heart Failure
(6)
Epidemiology
(6)
Glucose
(6)
Heart Failure
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-Time

870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study

270-OR: Health Care Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes—Results from the EMPRISE study

1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study

Effectiveness and safety of empagliflozin: final results from the EMPRISE study

Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data

179-OR: Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

1079-P: Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Stratified analysis in comparative effectiveness studies that emulate randomized trials

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Renin–Angiotensin–Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

A Systematic Approach to Evaluating Instrumental Variable Assumptions: Applied Example of Glucose-lowering Medications and Risk for Hospitalized Heart Failure in Older Adults

Estimating Treatment Effects in the Presence of Calendar Time Trends in Prescribing: Instrumental Variables and Trend-In-Trend Design

Unmeasured confounding with and without randomization

Chapter 14 - Unmeasured confounding with and without randomization

Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme

Suchergebnisse filtern